A Durable Response With the Combination of Nivolumab and Cabozantinib in a Patient With Metastatic Paraganglioma: A Case Report and Review of the Current Literature.

ABSTRACT:

Introduction

Pheochromocytomas and sympathetic paragangliomas (PPGL) are neuroendocrine catecholamine-secreting tumors that are usually localized. Metastatic disease is rare and systemic treatment consists of conventional chemotherapy and high-specific-activity iodine-131-MIBG which was approved by the FDA in 2018. Although chemotherapy combinations still have value in specific settings, the debilitating side effects of treatment with only modest benefit have limited their use. With the introduction of a new generation of targeted therapy and immunotherapy patients with metastatic PPGL may have improved therapeutic options.

Areas covered

The current paper presents a case of a patient with metastatic PPGL who received multiple lines of systemic treatment. Despite progression

SUBMITTER: Economides MP 

PROVIDER: S-EPMC7731902 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature